Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says
CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.
You may also be interested in...
PhRMA’s Opening Gambit: Limiting Medicare Price Setting To The IRA's Minimum Discount
CMS should adopt the minimum price reductions under the Inflation Reduction Act for most selected drugs in the early years of the Medicare price negotiation program, PhRMA urges and recommends the agency should retain that approach in the long-term for younger drugs, those targeting an unmet medical need or those representing therapeutic advances.
Medicare Price Negotiation And A New Twist On Product Hopping
Tactic generally used to foil generic or biosimilar competition may find a new use in combination with such competition to avoid price negotiation, legal experts observe.
A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations
Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.